Which diabetes drug best protects your heart? 60,000-person study aims to find out.
NCT ID NCT07417618
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large study looks at real-world data from 60,000 people with type 2 diabetes and obesity to compare four diabetes drugs—dulaglutide, semaglutide, tirzepatide, and sitagliptin—in preventing heart attacks, strokes, and death. Researchers are analyzing insurance claims to see which drug works best, both in people with and without existing heart disease. The goal is to guide doctors in choosing the most effective treatment for heart protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dulaglutide, semaglutide, tirzepatide, sitagliptin
What this could lead to
If successful, this could show which diabetes drug is best at preventing heart attacks and strokes in people with type 2 diabetes and obesity.
What could go wrong
This is an observational study using existing data, not a controlled experiment, so results may be less reliable. It also compares drugs already on the market, so no new treatment is being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States